Why triphala has an eye reputation: provenance and the research line

An orally taken laxative with an eye indication is an odd thing, and it is worth asking how that happened.

Triphala’s eye reputation is not a modern marketing invention. It is specific, it is textual, and there is a modern research thread that runs alongside it in an interesting way.

This article is the provenance, where the claim comes from, what each fruit is said to contribute, and what the research line actually consists of.

The practical side, the eye wash, and why we argue against it, is a separate article, and anyone considering putting anything in their eyes should read that one instead of this one.

This is information, not medical advice. Do not put anything in your eyes without an ophthalmologist’s advice. Our separate article sets out why.

Where the claim comes from

The classification

Triphala is designated chakshushya, beneficial to the eyes, and that designation is explicit rather than inferred.

And the designation belongs principally to one of the three fruits: amalaki. Amla is classically chakshushya in its own right, and it carries that attribution into the blend.

Haritaki also appears in eye contexts in the classical literature, and bibhitaki less so.

So the eye reputation is not evenly distributed across the three. It comes mainly from amla, and the blend inherits it.

That is worth knowing, because it means the eye claim is really an amla claim with two other fruits attached, and a buyer choosing between Triphala and amla for this purpose is choosing between a blend and the component that carries the attribution.

Why an oral laxative acquired an eye indication

Two strands, and both are coherent within the framework.

First, the pitta connection. In the classical framework, eye disorders are substantially attributed to pitta, and particularly to pitta in the upper body. Amla is pitta-pacifying and classically cooling (sheeta in virya). So a pitta-pacifying agent is a logical choice for an eye indication within that system.

Second, the rasayana logic. Triphala is a rasayana and vayasthapana, age-sustaining. And age-related visual decline is exactly what a vayasthapana agent would be directed at.

So within its own framework the reasoning is internally consistent, the eye indication follows from the properties, rather than being bolted on.

And a third, more prosaic point: the classical preparations for eyes are mostly not the oral churna. They are netra tarpana (a ghee preparation held over the eye), netra prakshalana (eye wash), ashchyotana (drops), and Triphala ghrita (a medicated ghee). The oral rasayana use and the topical eye use are different practices that share an ingredient, and modern marketing collapses them.

The classical formulations

Triphala ghrita, medicated ghee, and the best-known classical eye preparation containing it.

Mahatriphala ghrita, an extended formulation.

And Triphala features in classical eye-disease chapters across the texts, including in contexts that would now be read as conjunctivitis, lens changes and general visual decline.

These are licensed as classical Ayurvedic medicines where made to the texts, and that licensing distinction governs what a label may say.

What each fruit is said to contribute

Set out plainly, because the three are not interchangeable here.

Amalaki (amla), the chakshushya attribution itself, the cooling and pitta-pacifying action, and the vitamin C. This is the fruit the eye reputation rests on.

Haritaki, the anulomana and regulating action, and some classical eye-context use. And in the classical reading, correcting the downward movement of vata is held to matter for conditions of the head, which is the framework’s own logic rather than a modern mechanism.

Bibhitaki, the kapha-reducing dimension, which in classical eye contexts relates to conditions with discharge and heaviness.

And a modern observation that runs parallel: all three are tannin- and polyphenol-rich, so the blend carries a broader antioxidant profile than any one alone. That is an observation about composition, not evidence of a visual benefit.

The research line

This is the part worth knowing, because there is a specific modern thread and it is more interesting than the general antioxidant story.

Aldose reductase

The most coherent modern line runs through this enzyme.

Aldose reductase catalyses the conversion of glucose to sorbitol via the polyol pathway.

And in hyperglycaemia, that pathway becomes significant, sorbitol accumulates inside cells, draws in water osmotically, and this mechanism is implicated in diabetic cataract and in other diabetic complications.

Aldose reductase inhibition is accordingly a studied drug target for diabetic eye disease.

And several Triphala components, particularly the gallotannins and ellagitannins, have been reported to inhibit aldose reductase in laboratory systems.

Which gives the eye claim a specific, mechanistic modern thread rather than a vague antioxidant one.

And the limits, which are substantial:

This is enzyme inhibition in vitro. Whether orally taken Triphala reaches the lens at concentrations that inhibit aldose reductase meaningfully is not established, and the lens has a particular permeability situation.

Animal cataract models, Triphala and its components have been reported to delay lens opacity in chemically or galactose-induced models. Those models are a long way from human age-related cataract, which is a different process.

And there is no human trial of oral Triphala for cataract prevention or progression. None.

So the thread is real and it is thin. It is the most interesting thing in this article and it does not support a claim.

The other research strands

Antioxidant activity, extensively documented in vitro, and the retina is a tissue with genuine oxidative vulnerability. General rather than specific.

Dry eye and computer vision syndrome, small human studies exist, including on Triphala ghrita and Triphala-containing preparations, reporting symptom improvement. Small, short, frequently unblinded, and multi-ingredient.

Anti-inflammatory and antimicrobial activity in vitro, including against organisms relevant to ocular surface infection, which is laboratory work and is not a basis for using it on an eye.

And the dental work, Triphala mouthwash on plaque and gingivitis has the most reasonable human evidence of anything in the Triphala literature. It is not an eye application, and it is worth mentioning because it shows what a decent evidence base for this ingredient looks like, by contrast.

The honest grading

Classical standing: explicit and textual. Triphala is chakshushya, principally via amla.

Internal coherence: good. The eye indication follows from the framework’s own logic.

Modern mechanistic thread: specific and interesting. Aldose reductase inhibition, with a plausible link to diabetic lens changes.

Human evidence: essentially absent for the eye. Small studies on dry eye symptoms; nothing on cataract or on vision.

And that combination, strong classical standing plus an interesting mechanism plus no human outcome data, is the normal state of affairs for Ayurvedic ingredients. It is a reasonable thing to sell as a traditional preparation. It is not an eye treatment.

What this means for a buyer

Four practical conclusions.

1. If you want the eye-associated component, amla is where the attribution sits. And fresh amla or amla juice delivers more vitamin C than Triphala churna does, because it is one fruit rather than a third of the blend. We have written about amla in detail.

2. The classical eye preparations are topical, and we advise against the home versions. Triphala ghrita and the eye washes are different practices from the oral churna, and our separate article sets out the sterility, Acanthamoeba and corneal astringency arguments in full. Our products carry “for oral use only, do not apply to the eyes.”

3. The oral rasayana use is a legitimate traditional practice, for a defined period, with the laxative effect and the drug-spacing cautions managed, which our other articles cover.

4. And nothing here substitutes for an eye examination. Glaucoma and diabetic retinopathy are silent and cause irreversible loss, and in diabetes an annual dilated examination is the intervention that matters, regardless of how good the vision seems. That is the single most useful sentence in this article and it has nothing to do with Triphala.

Licensing, and why this matters here

A classical Triphala eye preparation made to a First Schedule text and licensed as an Ayurvedic medicine may carry that text’s indications.

A Triphala churna, capsule or juice sold as a food supplement under FSSAI may make no medicinal claims at all.

And the Drugs and Magic Remedies (Objectionable Advertisements) Act applies regardless of licence.

And this is one of the clearest examples of why the distinction matters: the classical texts give Triphala eye indications, and a food supplement cannot print them. Doing so is the commonest violation in this category, and in the eye context it is also the most consequential, because delayed presentation for glaucoma or diabetic retinopathy costs sight permanently.

Claims, what we print and refuse

What is sayable: a traditional-use statement, that Triphala has long traditional use in Ayurveda as a rasayana and is classically described as chakshushya, framed clearly as traditional use, plus authorised nutrient-function claims where the formulation qualifies: vitamin A, riboflavin and zinc contribute to the maintenance of normal vision; vitamin C contributes to the protection of cells from oxidative stress.

And note the wording of the authorised claim: “maintenance of normal vision”, not “improves vision”. That distinction is deliberate.

And there is no authorised health claim for Triphala.

What is not sayable: improves eyesight, prevents or treats cataract, treats glaucoma, treats dry eye, reduces spectacle power, or protects against screen damage.

What we require on artwork: “for oral use only, do not apply to the eyes.” That line exists specifically because of the classical eye-wash practice, and almost nobody in this category prints it.

And what we decline: any cataract claim; any “improves eyesight” claim; and any product aimed at children’s eyesight.

The short version

1. The eye reputation is textual and specific, not a modern invention.
2. Triphala is designated chakshushya, beneficial to the eyes.
3. The designation belongs principally to amla, which is chakshushya in its own right.
4. So the eye claim is really an amla claim with two other fruits attached.
5. Within the framework the logic is consistent: eye disorders are attributed substantially to pitta, and amla is pitta-pacifying.
6. And vayasthapana, age-sustaining, maps onto age-related visual decline.
7. The classical eye preparations are mostly topical, not the oral churna.
8. Triphala ghrita is the best-known classical eye formulation.
9. Oral rasayana use and topical eye use are different practices sharing an ingredient, marketing collapses them.
10. Haritaki contributes the anulomana action; bibhitaki the kapha-reducing dimension.
11. All three are tannin- and polyphenol-rich, a composition observation, not a visual benefit.
12. The most coherent modern thread is aldose reductase inhibition.
13. That enzyme converts glucose to sorbitol, and the pathway is implicated in diabetic cataract.
14. Triphala’s gallotannins and ellagitannins inhibit it in vitro.
15. Whether oral Triphala reaches the lens at inhibitory concentrations is not established.
16. Animal cataract models are induced models, a long way from human age-related cataract.
17. There is no human trial of oral Triphala for cataract. None.
18. Small human studies exist on dry eye symptoms, small, short, often unblinded.
19. The best human evidence in the whole Triphala literature is for a mouthwash.
20. Strong classical standing plus an interesting mechanism plus no human outcome data is the normal state for this category.
21. For the eye-associated component, fresh amla delivers more vitamin C than a third of a blend.
22. The classical eye washes are a practice we argue against, see our separate article.
23. The authorised claim is “maintenance of normal vision”, not “improves vision”.
24. A food supplement cannot print a classical text’s eye indications.
25. And in the eye context that violation is the most consequential, delayed presentation costs sight.
26. An eye examination matters more than any of this, and in diabetes, annually.

Ingredient detail: triphala and amla. Composition: triphala powder and Optimo 360. Related: triphala for eyes, the classical use and the practice we advise against, आँखों की रोशनी बढ़ाने के उपाय, and the three fruits and the ratio question.